20 citations
,
January 2017 in “Epilepsia” Blocking neurosteroid production can lead to more seizures and faster epilepsy onset in rats.
1 citations
,
July 2025 in “The Open Dermatology Journal” Tissue engineering in cosmetics offers safer, more effective products and ethical alternatives to animal testing.
5 citations
,
February 2022 in “Acta Biomaterialia” Nanomaterials can improve hair care products and treatments, including hair loss and alopecia, by enhancing stability and safety, and allowing controlled release of compounds, but their safety in cosmetics needs more understanding.
2 citations
,
January 2023 in “Pharmaceuticals” Natural products and phytochemicals may help with hair regrowth, but more research is needed.
1 citations
,
May 2024 in “Pharmaceutics” Hemp is a promising ingredient for skin products due to its healing and soothing properties.
November 2024 in “Applied Sciences” Placenta products might help with hair loss, but more research is needed.
213 citations
,
September 2020 in “Journal of Functional Biomaterials” Bio-based electrospun fibers improve wound healing but face production and regulatory challenges.
3 citations
,
June 2023 in “Medicina” No medications for alcohol dependence have been approved for marketing yet.
4 citations
,
February 2015 in “PubMed” The emu oil emulsion with minoxidil was better at promoting hair growth than the commercial product.
2 citations
,
July 2023 in “Phytotherapy Research” Serenoa repens is mostly safe but has some risks, especially at high doses or when used with other products for over two weeks.
20 citations
,
April 2021 in “Journal of Womens Health” Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.
4 citations
,
April 2022 in “Microorganisms” Povidone iodine reduced skin bacteria more than chlorhexidine gluconate, but neither met FDA reduction standards.
4 citations
,
December 2022 in “Frontiers in Bioengineering and Biotechnology” Exosomes show promise for improving wound healing, reducing aging signs, preventing hair loss, and lightening skin but require more research and better production methods.
Using too much topical minoxidil can cause serious side effects like dizziness and low blood pressure.
July 2025 in “International Journal of Dermatology” Topical finasteride may be safer than oral finasteride, but more research is needed.
2 citations
,
July 2022 in “Sexual Medicine” Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
June 2025 in “Nanomedicine” Nanotechnology could improve hair loss treatments by delivering drugs more effectively.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
1 citations
,
May 2013 in “Oncology Times” ODAC members faced intense pressure but prioritized scientific evidence in drug approval decisions.
18 citations
,
June 2017 in “Oncotarget” Digoxin is linked to a higher risk of anemia in patients with atrial fibrillation and heart failure.
23 citations
,
September 2021 in “Clinical Cosmetic and Investigational Dermatology” Botulinum toxin is used in skin care for cosmetic and medical purposes.
2 citations
,
September 2023 in “Cosmetics” Cannabinoids may help some skin conditions but more research is needed.
21 citations
,
November 2023 in “Heliyon” Tropical herbs are better for hair care than synthetic additives.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
1 citations
,
January 2023 in “Indian Dermatology Online Journal” Skin and nail changes are common in patients with blood cancers undergoing chemotherapy, affecting their quality of life.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.